Scientists at Sanofi created digital counterparts of people with Pompe disease to support drug development and advance Pompe disease treatment. In a simulated clinical trial of digital twins with infantile-onset Pompe disease (IOPD), Sanofi’s Nexviazyme (avalglucosidase alfa), an enzyme replacement therapy, outperformed its first-generation Lumizyme (alglucosidase alfa)…
AI
Recent Posts
- How my daughter’s medical backpack became a symbol of freedom
- Lung function test may catch respiratory issues in late-onset Pompe
- Wanting to blend in, so the rare care isn’t the first thing that’s seen
- Home enzyme replacement therapy safe for Pompe disease children
- What ‘lucky’ really means for a child with Pompe disease